Hematologic disorders associated with ischemic stroke

Journal of the Neurological Sciences

Volumn 140, Issue 1-2, 1996, Pages 1-11

  Tatlisumak, Turgut ^a,b   Fisher, Marc ^a,c  

^a Med Ctr Ctrl Massachusetts Mem   (United States)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Anticoagulant; Antiphospholipid; Coagulation; Heparin; Hypercoagulable state; Ischemic stroke; Thrombosis; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; HEPARIN; WARFARIN;

CEREBROVASCULAR ACCIDENT; HUMAN; HYPERCOAGULABILITY; PRIORITY JOURNAL; REVIEW; SKIN NECROSIS; THROMBOCYTOPENIA; THROMBOSIS;

EID: 0030245860     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0022-510X(96)00051-2     Document Type: Review

References (150)

1. Adams, H.P., Jr., Butler, M.J., Biller, J. and Toffol, G.J. (1986) Nonhemorrhagic cerebral infarction in young adults. Arch. Neurol., 43: 793-796.
2. Adams, R.J., Nichols, F.T., McVie, V., Milner, P. and Gammal. T.E. (1988) Cerebral infarction in sickle cell anemia: mechanism based on CT and MRI. Neurology 38: 1012-1017.
3. Adams, R.J., Kutlar, A., McKie, K., Carl, E., Nichols, F.T., Liu, J.C., McKie, K. and Clary, A. (1994) Alpha thalassemia and stroke risk in sickle cell anemia. Am. J. Hematol., 45: 279-282.
4. Adams, R.J. (1995) Sickle cell anemia and stroke. J. Child Neurol., 10: 75-76. [Editorial]
5. Anderson, T., Larsen, M. and Abildgaard, U. (1987) Low heparin cofactor II associated with abnormal crossed immunoelectrophoresis pattern in two Norwegian families. Thromb. Res., 47: 243-248.
6. APASS (The Antiphospholipid Antibodies in Stroke Study) Group (1990): Clinical and laboratory findings in patients with antiphospholipid antibodies and cerebral ischemia. Stroke, 21: 1268-1273.
7. APASS (The Antiphospholipid Antibodies in Stroke Study) Group (1993): Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. Neurology, 43: 2069-2073.
8. Asherson, R.A., Mercey, D., Phillips, G., Sheehan, N., Gharavi, A.E., Harris, E.N. and Hughes. G.R. (1987) Recurrent stroke and multi-infarct dementia in systemic lupus erythematosus associated with antiphospholipid antibodies. Ann. Rheum. Dis., 46: 605-611.
9. Atkinson, J.L.D., Sundt, T.M., Kazmier, F.J., Bowie, E.J.W. and Whisnant, J.P. (1988) Heparin-induced thrombocytopenia and thrombosis in ischemic stroke. Mayo Clin. Proc., 63: 353-361.
10. Babikian, V.L. and Levine, S.R. (1992) Therapeutic considerations for stroke patients with antiphospholipid antibodies. Stroke, 23 [suppl. I]: 1-33-1-37.
11. Bale, J.F., Brasler, C. and Siegler, R.L. (1980) CNS manifestations of hemolytic uremic syndrome: relationship to metabolic alterations and prognosis. Am. J. Dis. Child., 134: 869-872.
12. Bulkaran, B., Char, G., Morris, J.S., Thomas, P.W., Serjeant, B.E. and Serjeant, G.R. (1992) Stroke in a cohort of patients with homozygous sickle cell disease. J. Pediatr., 120: 360-366.
13. Barinagarrementeria, F., Cant, Cantú-Brito, C., De La Peña, A. and Izaguirre, R. (1994) Prothrombotic states in young people with idiopathic stroke. A prospective study. Stroke, 25: 287-290.
14. Bauer, K.A. (1994) Hypercoagulability - a new cofactor in the protein C anticoagulant pathway. New. Engl. J. Med., 330: 566-567.
15. Becker, P.S. and Miller, V.T. (1989) Heparin-induced thrombocytopenia. Stroke, 20: 1449-1459.
16. Ben-Tal, O., Zivelin, A. and Seligsohn, U. (1989) The relative frequency of hereditary thrombotic disorders among 107 patients with thrombophilia in Israel. Thromb. Haemost., 61: 50-54.
17. Bertina, R.M. (1985) Hereditary protein S deficiency. Haemostasis, 15: 241-246.
18. Bertina, R.M., Van der Linden, I.K., Engesser, L., Muller, H.P. and Brommer, E.J. (1987) Hereditary heparin co-factor II deficiency and the risk of development of thrombosis. Thromb. Haemost., 57: 196-200.
19. Bertina, R.M., Koeleman, B.P.C., Rosendaal, F.R., Dirven, R.J., De Honde, H., Van der Velden, P.A. and Reitsma, P.R. (1994) Mutation in the blood coagulation factor V associated with resistance to activated protein C. Nature, 369: 64-67.
20. Bevan, H., Sharma, K. and Bradley, W. (1990) Stroke in young adults. Stroke, 21: 382-386.
21. Bevers, E.M., Galli, M., Barbui, T., Comfurius, P. and Zwaal, R.F. (1991) Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb. Haemost. 66: 629-632.
22. Bick, R.L. (1982) Clinical relevance of antithrombin III. Semin. Thromb. Hemost., 8: 276-287.
23. Bick, L.R. and Ucar, K. (1992) Hypercoagulability and thrombosis. Hemat. Oncol. Clin. North Am., 6: 1421-1431.
24. Bick, L.R. and Baker, W.F. (1994) Antiphospholipid and thrombosis syndromes. Semin. Thromb., 20: 3-15.
25. Bick, R.L. and Pegram. M. (1994) Syndromes of hypercoagulability and thrombosis: a review. Semin. Thromb. Hemost., 20: 109-132.
26. Bock, S.C., Harris, J.F., Balazs, I. and Trent, J.M. (1985) Assignment of the human antithrombin III structural gene to chromosome Iq23-q25. Cytogenet. Cell Genet., 39: 67-69.
27. Boerger, L.M., Morris, P.C., Thurnau, G.R., Esmon, C.T. and Comp, P.C. (1987) Oral contraceptives and gender effect on protein-S status. Blood. 69: 692-694.
28. Bogousslavsky, J., Van Melle, G. and Regli. F. (1988) The Lausanne stroke registry: analysis of 1000 consecutive patients with first stroke. Stroke, 19: 1083-1092.
29. Bogousslavsky, J. (1992) Stroke in young adults. In: Barnett, H.J.M., Mohr, J.P., Stein, B.M., Yatsu, F.M., editors. Stroke: Pathophysiology, Diagnosis, and Management. 2nd edn., Churchill Livingstone. New York. pp. 895-901.
30. Brey, R.L., Hart, R.G., Sherman, D.G. and Tegeler, C.H. (1990) Antiphospholipid antibodies and cerebral ischemia in young people. Neurology. 40: 1190-1196.
31. Briley, D.P., Coull, B.M. and Goodnight, S.H. (1989) Neurological disease associated with antiphospholipid antibodies. Ann. Neurol., 25: 221-227.
32. Broekmans, A.W., Van der Linden, I.K., Jansen, Y.-Koeter and Bertina, R.M. (1986) Prevalence of protein C (PC) and protein S (PS) deficiency in patients with thromhotic disease. Thromb. Res., (suppl. VI): 268.
33. Camerlingo, M., Finazzi, G., Casto, L., Laffranchi, C., Barbui, T. and Mamoli, A. (1991) Inherited protein C deficiency and nonhemorrhagic arterial stroke in young adults. Neurology, 41: 1371-1373.
34. Cariou, R., Tobelem, G., Bellucci, S., Soria, J., Soria, C., Maclouf, J. and Caen, J. (1988) Effect of lupus anticoagulant on antithrombogenic properties of endothelial cells: inhibition of thrombomodulin-dependent protein C activation. Thromb. Haemost., 60: 54-59.
35. Carreras, L.O. and Veraylan, J.G. (1982) Lupus anticoagulant and thrombosis: possible role of inhibition of prostacyclin formation. Thromb. Haemost., 48: 38-40.
36. Chancellor, A.M., Glasgow, G.L., Ockelford, P.A., Johus, A. and Smith, J. (1989) Etiology, prognosis, and hemostatic function after cerebral infarction in young adults. Stroke, 20: 477-182.
37. Cheatham, M.L. and Brackett, C.E. (1965) Problems in the management of subarachnoidal hemorrhage in sickle cell anemia. J. Neurosurg. 23: 488-493.
38. Chimowitz, M., Mansbach, H., Schmaier, A., Nichols, W. and Ginsburg, D. (1996) Factor V mutation and cryptogenic stroke in the young. Stroke 27: 188 [Abstract].
39. Clause, H.L. and Comp, P.C. (1983) The regulation of hemostasis: the protein C system. N. Engl. J. Med., 314: 1298-1304.
40. Coller, B.S., Owen, J., Jesty, J., Horowitz, D., Reitman, M.J., Spear, J., Yeh, T. and Comp, P.C. (1987) Deficiency of plasma protein S. protein C or antithrombin III and arterial thrombosis. Arteriosclerosis, 7: 456-461.
41. Cortelazzo, S., Finazzi, G., Ruggeri, M., Vestri, O., Galli, M., Rodeghiero, F. and Barbui, T. (1995) Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N. Engl. J. Med., 332: 1132-1136.
42. Coull, B.M. and Goodnight, S.H. (1990) Antiphospholipid antibodies. prethrombotic states and stroke. Stroke, 21: 1370-1374.
43. Coull, B.M., Levine, S.R. and Brey, R. (1992) The role of antiphospholipid antibodies in stroke. Neur. Clin., 10: 125-143.
44. Coull, B.M. and Clark, W.M. (1993) Abnormalities of hemostasis in ischemic stroke. Med. Clin., 77: 77-94.
45. Cushman, M., Bhushan, F., Bovill, E. and Tracy, R. (1994) Plasma resistance to activated protein C in venous and arterial thrombosis [letter]. Thromb. Haemost., 72: 647.
46. Dahlbäck, B., Carlsson, M. and Svensson, P.J. (1993) Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc. Natl. Acad. Sci. USA, 90: 1004-1008.
47. Davis, W.D. and Brey, R.L. (1991) Complement activation in stroke associated with antiphospholipid antibodies [abstract]. Neurology, 41 (suppl. 1): 296.
48. Davous, P., Horellou, M., Conard, J. and Samama, M. (1990) Cerebral infarction and familial protein S deficiency. Stroke, 21: 1760-1761.
49. Devilat, M., Toso, M. and Morales, M. (1993) Childhood stroke associated with protein C or protein S deficiency and primary antiphospholipid syndrome. Pediatr. Neurol., 9: 67-70.
50. Dolan, G., Greaves, M., Cooper, P. and Preston, F.E. (1988) Thrombovascular disease and familial plasminogen deficiency: a report of three kindreds. Br. J. Haematol., 70: 417-421.
51. Doll, D.C. and Greenberg, B.R. (1985) Cerebral thrombosis in smoker's polycythemia. Ann. Intern. Med., 102: 786-787.
52. Eby, C.S. (1993) Warfarin-induced skin necrosis. Hematol. Oncol. Clin. North Am., 7: 1291-1300.
53. El-Roeiy, A. and Gleicher, N. (1988) Definition of normal autoantibody levels in an apparently healthy population. Obstet. Gynecol., 72: 596-602.
54. Feinberg, W.M. and Swenson, M.R. (1988) Cerebrovascular complications of L-asparaginase therapy. Neurology, 38: 127-133.
55. Fields, R.A., Toubbeh, H., Searles, R.P. and Bankhurst, A.D. (1989) The prevalence of anticardiolipin antibodies in a healthy elderly population and its association with antinuclear antibodies. J. Reumatol., 16: 623-625.
56. Furlan, A.J., Lucas, F.V., Wohl, R.C. and Craciun, A.R. (1985) Stroke in a young adult with a familial plasminogen disorder [abstract]. Ann. Neurol., 18: 122.
57. Galli, M., Comfurius, P., Maassen, C., Hemker, H.C., De Baets, M.H., Van Breda-Vriesman, P.J.C., Barbui, T., Zwaal, R.F.A. and Bevers, E.M. (1990) Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet, 335: 1544-1547.
58. 2-glycoprotein I. Lupus, 1 (suppl. 1): 150.
59. Gladson, C.L., Scharrer, I., Hach, V., Beck, K.H. and Griffin, J.H. (1988) The frequency of type I heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis. Thromb. Haemost., 59: 18-22.
60. Glauser, T.A., Siegel, M.J. and DeBaun, M.R. (1995) Accuracy of neurologic examination and history in detecting evidence of MRI-diagnosed cerebral infarctions in children with sickle cell hemoglobinopathy. J. Child Neurol., 10: 88-92.
61. Green, D., Otoya, J., Oriba, H. and Rovner, R. (1992) Protein S deficiency in middle-aged women with stroke. Neurology. 42: 1029-1033.
62. Grewal, R.P. and Goldberg, M.A. (1990) Stroke in protein C deficiency. Am. J. Med., 89: 538-539.
63. Griffin, J.H., Evatt, B., Wideman, C. and Fernandez, A. (1993) Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood. 82: 1989-1993.
64. Griffith, M.J. (1982) Kinetics of the heparin-enhanced antithrombin III/thromhin reaction. Evidence for a template model for the mechanism of action of heparin. J. Biol. Chem., 257: 7360-7365.
65. Grindal, A.B., Cohen, R.J., R.F Saul and Taylor, J.R. (1978) Cerebral infarction in young adults. Stroke, 9: 39-42.
66. Gruber, A., Pál, A., Kiss, R.G., Sas, G. and Griffin, J.H. (1993) Generation of activated protein C during thrombolysis. Lancet, 342: 1275-1276.
67. Hahn, J.S., Havens, P.L., Higgins, J.J., O'Rourke, P.P., Estroff, J.A. and Strand, R. (1989) Neurological complications of hemolytic-uremic syndrome. J. Child Neurol., 4: 108-113.
68. Haire, W.D. and Newland, J.R. (1990) Protein C deficiency and anticardiolipin antibodies in a family with premature stroke. Am. J. Hematol., 33: 61-63.
69. Halbmayer, W.M., Haushofer, A., Schön, R. and Fischer, M. (1994) The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis among healthy subjects. Blood Coagul. Fibrinol., 5: 54-59.
70. Hamsten, A., Wiman, B., De Faire, U. and Blombäck. A.M. (1985) Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N. Engl. J. Med., 313: 1557-1563.
71. Harris, E.N. (1992) Serological detection of antiphospholipid antibodies. Stroke, 23 [suppl. I]: I-3-I-6.
72. Hart, R.G. and Miller, V.T. (1983) Cerebral infarction in young adults: a practical approach. Stroke, 14: 110-114.
73. Hart R.G. and Kanter, M.C. (1990) Hematologic disorders and ischemic stroke: a selective review. Stroke, 21: 1111-1121.
74. Hathaway, W.E. (1991) Clinical aspects of antithrombin III deficiency. Semin. Haematol., 28: 19-23.
75. Hess, D.C., Adams, R.J. and Nichols, F.T. (1991) Sickle cell anemia and other hemoglobinopathies. Semin. Neurol., 11: 314-328.
76. High, K.A. (1988) Antithrombin III, protein C, and protein S. Arch. Pathol. Lab. Med., 112: 28-36.
77. Hirsh, J. (1989) Congenital antithrombin III deficiency: incidence and clinical features. Am. J. Med., 87 (suppl. 3B) 34-38.
78. Hughes, G.R.V. (1993) The antiphospholipid syndrome: ten years on. Lancet, 342: 341-344.
79. Israels, S.J. and Seshia, S.S. (1987) Childhood stroke associated with protein C or protein S deficiency. J. Pediatr., 111: 562-564.
80. Joist, J. (1990) Hypercoagulability: introduction and perspective. Semin. Thromb. Hemost., 16: 151-157.
81. Jorgensen, M. and Bonnevie-Nielsen, V. (1987) Increased concentration of the fast-acting plasminogen activator inhibitor in plasma associated with familial venous thrombosis. Br. J. Haematol., 65: 175-180.
82. Kannel, W.B., Wolf, P.A., Castelli, W.P. and D'Agostina, R.B. (1987) Fibrinogen and risk of cardiovascular disease: the Framingham Study. J. Am. Med. Ass., 258: 1183-1186.
83. Kelles, A., Van Dyck, M. and Proesmans, W. (1994) Childhood haemolytic uraemic syndrome: long-term outcome and prognostic features. Eur. J. Pediatr., 153: 38-42.
84. Kessler, C.M., Klein, H.G. and Havlik, R.J. (1982) Uncontrolled thrombocytosis in chronic myeloproliterative disorders. Br. J. Haematol., 50: 157-162.
85. Khamashta, M.A., Cuadrado, M.J., Mujic, F., Taub, N.A., Hunt, B.J. and Hughes, G.R.V. (1995) The management of thrombosis in the antiphospholipid-antibody syndrome. N. Engl. J. Med., 332: 993-997.
86. Kocak, R., Alparslan, Z.N., Agridag, G., Baslamisli, F., Aksungur, P.D. and Koltas, S. (1995) The frequency of anaemia, iron deficiency, hemoglobin S, and beta thalassemia in the south of Turkey. Eur. J. Epidemiol., 11: 181-184.
87. Kohler, J., Kasper, J., I. Witt and G.M. von Reutern (1990) Ischemic stroke due to protein C deficiency. Stroke, 21: 1077-1080.
88. Kontula, K., Ylikorkola, A., Miettinen, H., Vuorio, A., Kauppinen, R.-Mäkelin, L. Hämäläinen, H. Palomäki and Kaste. M. (1995) Arg506Gln factor V mutation (Factor V Leiden) in patients with ischaemic cerebrovascular disease and survivors of myocardial infarction. Thromb. Haemost., 73: 558-560.
89. Koster, T., Rosendaal, F.R., De Honde, H., Briët, E., Vandenbroucke, J.P. and Bertina, R.M. (1993) Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet, 343: 1503-1506.
90. Kottke-Marchant, K. (1994) Laboratory diagnosis of hemorrhagic and thrombotic disorders. Hematol/Oncol. Clin. North Am., 8: 809-853.
91. Lane, D.A. and Caso, R. (1989) Antithrombin: structure, genomic organization, function and inherited deficiency. Clin. Haem., 2: 961-998.
92. Lisovoski, F. and Rousseaux, P. (1991) Cerebral infarction in young people. A study of 148 patients with early cerebral angiography. J. Neurol. Neurosurg. Psychiatr., 54: 576-579.
93. Lottenberg, R., Dolly, F.R. and Kitchens, C.S. (1985) Recurring thromboembolic disease and pulmonary hypertension associated with severe hypoplasminogenemia. Am. J. Hematol., 19: 181-193.
94. Love, P.E. and Santoro, S.A. (1990) Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus and in non-SLE disorders. Ann. Intern. Med., 112: 682-698.
95. Lubarsky, D.A., Gallagher, C.J. and Berend, J.L. (1991) Secondary polycythemia does not increase the risk of perioperative hemorrhagic or thrombotic complications. J. Clin. Anest., 3: 99-103.
96. Malm, J., Bennhagen, R., Holmberg, L. and Dahlbäck, B. (1986) Plasma concentrations of C4b-binding protein and vitamin K-dependent protein S in term and preterm infants: low levels of protein S-C4b-binding protein complexes. Br. J. Haematol., 68: 445-449.
97. Martinez, R.A., Rangel-Guerra, H.R. and Marfil, L.J. (1993) Ischemic stroke due to deficiency of coagulation inhibitors. Report of 10 young adults. Stroke, 24: 19-25.
98. Massey, E.W. and Riggs, J.E. (1989) Neurologic manifestations of hematologic disease. Neurol. Clin., 7: 549-560.
99. Mayer, S.A., Sacco, R.L., Hurlet, A.-Jensen, Shi, T. and Mohr, J.P. (1993) Free protein S deficiency in acute ischemic stroke. Stroke, 24: 224-227.
100. 2 glycoprotein I. Proc. Natl. Acad. Sci, USA, 87: 4120-4124.
101. Menache, D. (1991) Replacement therapy in patients with hereditary antithrombin III deficiency. Semin. Hematol., 28: 31-38.
102. Menache, D. (1992) Antithrombin III concentrates. Hematol. Oncol. Clin. North Am., 6: 1115-1120.
103. Mettinger, K.L., Nyman, D., Kjellin, K.G., Siden, A. and Söderström, C.E. (1979) Factor III-related antigen, antithrombin III, spontaneous platelet aggregation, and plasminogen activator in ischemic cerebrovascular disease: a study of stroke before 55. J. Neurol. Sci., 41: 31-38.
104. Miletich, J., Sherman, L. and Broze, G. (1987) Absence of thrombosis in subjects with heterozygous protein C deficiency. N. Engl. J. Med., 317: 991-996.
105. Miletich, J.P. (1990) Laboratory diagnosis of protein C deficiency. Semin. Thromb. Hemost., 16: 169-176.
106. Montalbàn, J., Khamashta, M., Davalos, A., Codina, M., Swana, G.T., Calcagnotto, M.E., Sulalla, J., Mederer, S., Gil, A., Hughes, G.R.V. and Codina, A. (1994) Value of immunologic testing in stroke patients. A prospective multicenter study. Stroke, 25: 2412-2415.
107. Murphy, S., Iland, H., Rosenthal, D. and Laszlo, J. (1986) Essential thrombocythemia: an interim report of the polycythemia vera study group. Semin. Hematol., 23: 177-182.
108. Nathwani, A.C. and Tuddenham, E.G.D. (1992) Epidemiology of coagulation disorders. Clin. Haematol., 5: 383-439.
109. Odegaard, O.R. and Abildgaard, U. (1978) Antithrombin III: critical review of assay methods. Significance of variations in health and disease. Haemostasis, 7: 127-134.
110. Ohene-Frempong, K. (1991) Stroke in sickle cell disease: demographic, clinical, and therapeutic considerations. Semin. Hematol., 28: 213-219.
111. 2-glycoprotein I. Thromb. Haemost., 67: 499-502.
112. Oosting, J.D., Derksen, R.H.W.M., Bobbink, I.W.G., Hackeng, T.M., Bouma, B.N. and De Groot, P.G. (1993) Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin. protein C or protein S. An explanation for their pathogenic mechanism? Blood, 81: 2618-2625.
113. Pegelow, C.H., Adams, R.J., McKie, V., Abboud, M., Berman, B., Miller, S.T., Olivieri, N., Vichinsky, E., Wang, W. and Brambilla, D. (1995) Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J. Pediatr., 126: 896-899.
114. Powars, D., Wilson, B., Imbus, C., Pegelow, C. and Allen, J. (1978) The natural history of stroke in sickle cell disease. Am. J. Med., 65: 461-471.
115. Press, R.D., Liu, X.-Y., Beamer, N. and Coull, B.M. (1996) Ischemic stroke in the elderly. Role of the common factor V mutation causing resistance to activated protein C. Stroke, 27: 44-48.
116. Richards, D. and Nulsen, F.E. (1971) Angiographic media and the sickling phenomena. Surg. Forum, 22: 403-404.
117. Ridker, P.M., Hennekens, C.H., Lindpaintner, K., Stampfer, M.J., Eisenberg, P.R. and Miletich, J.P. (1995) Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N. Engl. J. Med., 332: 912-917.
118. Rooney, J.C., Anderson, R.M. and Hopkins, I.J. (1971) Clinical and pathological aspects of central nervous system involvement in the hemolytic uremic syndrome. Aust. Pediatr. J., 7: 28-33.
119. Rosenberg, R.D. (1975) Actions and interactions of antithrombin and heparin. N. Engl. J. Med., 292: 146-151.
120. Rosove, M.H., Hocking, W.G., Canobbio, M.M., Perloff, J.K., Child, J.S. and Skorton, D.J. (1986) Chronic hypoxaemia and decompensated erytbrocytosis in cyanotic congenital heart disease. Lancet 2: 313-315.
121. Rosove, M.H. and Brewer, P.M.C. (1992) Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann. Intern. Med., 117: 303-308.
122. Russell M.O., Goldberg, H.I., Hodson, A. Kim, H.C., Halus, J., Reivich, M. and Schwartz, E. (1984) Effect of transfusion therapy on arteriographic abnormalities and on recurrence of stroke in sickle cell disease. Blood, 63: 162-169.
123. Sacco, R.L., Owen, J., Mohr, J.P., Tatemichi, T.K. and Grossman, B.A. (1989) Free protein S deficiency: a possible association with cerebrovascular occlusion. Stroke, 20: 1657-1661.
124. Sandercock, P.A., Warlow, C.P., Jones, L.N. and Starkey, I.R. (1989) Predisposing factors for cerebral infarction: The Oxfordshire community stroke project. Br. Med. J., 298: 75-80.
125. Schafer, A.I. (1984) Bleeding and thrombosis in the myeloproliferative disorders. Blood, 64: 1-12.
126. Schafer, A.I. (1985) The hypercoagulable states. Ann. Intern. Med., 102: 814-828.
127. Schwarcz, T.H., Hogan, L.A., Endean, E.D., Roitman, I.T., Kazmers, A. and Hyde, G.L. (1993) Thromboembolic complications of polycythemia: polycythemia vera versus smokers' polycythemia. J. Vasc. Surg., 17: 518-523.
128. Sheth, K.J., Swick, H.M. and Haworth, N. (1986) Neurological involvement in hemolytic-uremic syndrome. Ann. Neurol., 19: 90-93.
129. Sie, P., Dupouy, D., Pichon, J. and Boneu, B. (1985) Constitutional heparin co-factor II deficiency associated with recurrent thrombosis. Lancet, ii: 414-416.
130. Sie, P., Boneu, B., Bierme, R., Wiesel, M.L., Grunebaum, L. and Cazenave, J.P. (1989) Arterial thrombosis and protein S deficiency. Thromb. Haemost., 62: 1040.
131. Simioni, P., Zanardi, S., Saracino, A. and Girolami, A. (1992) Occurrence of arterial thrombosis in a cohort of patients with hereditary deficiency of clotting inhibitors. J. Med., 23: 61-74.
132. Simioni, P., De Ronde, H., Prandoni, P., Saladini, M. and Bertina, R.M. (1995) Ischemic stroke in young patients with activated protein C resistance. A report of three cases belonging to three different kindreds. Stroke, 26: 885-890.
133. Stenflo, J. (1984) Structure and function of protein C. Semin. Thromb. Hemost., 10: 109-121.
134. Stockman, J.A., Nigro, M.A., Mishkin, M.M. and Oski, F.A. (1972) Occlusions of large cerebral vessels in sickle cell anemia. N. Engl. J. Med., 287: 846-849.
135. Svensson, P.J. and Dahlbäck, B. (1994) Resistance to activated protein C as a basis to venous thrombosis. N. Engl. J. Med., 330: 517-522.
136. Synder, B.D. and Ramirez-Lassepas, M. (1980) Cerebral infarction in young adults. Stroke, 11: 149-153.
137. Tartaglia, A.P., Goldberg, J.D. and Wasserman, L.R. (1986) Adverse effects of antiaggregating platelet therapy in the treatment of polycytemia vera. Semin. Hematol., 33: 172-176.
138. Tatlisumak, T., M. Syrjälä, Lindsberg, P., Palotie, A. and Kaste, M. (1995) FV-Arg-506-Gln mutation-associated resistance to activated protein C in ischemic stroke. J. Stroke Cerebrovasc. Dis. 5: 192-196.
139. Tengborn, L., Larsson, S.A., Hedner, U. and Nilsson, I.M. (1981) Coagulation studies in children and young adults with cerebral ischemic episodes. Acta Neurol. Scand., 63: 351-361.
140. Tran, T.H., Marbet, G.A. and Duckert, F. (1985) Association of hereditary heparin co-factor II deficiency with thrombosis. Lancet, ii: 413-414.
141. Trevathan, E. and Dooling, E.C. (1987) Large thrombotic strokes in hemolytic-uremic syndrome. J. Pediatr., 111: 863-866.
142. Tsakiris, D.A., Marbet, G.A., Makris, P.E., Settas, L. and Duckert, F. (1989) Impaired fibrinolysis as an essential contribution to thrombosis in patients with lupus anticoagulant. Thromb. Haemost., 61: 175-177.
143. Tuddenham, E.G.D. (1993) Thrombophilia: a new factor emerges from the mists. Lancet, 342: 1501-1502.
144. Vaarala, O., Alfthan, G., Jauhiainen, M., Leirisalo, M.-Repo, Aho, K. and Palosua, T. (1993) Cross-reaction between antibodies to oxidised low-density lipoprotein and to cardiolipin. Lancet, 341: 923-925.
145. Virchow, R. (1856) Phlogose und Thrombose. In: Gesammelte Abhandlungen zur Wissenschaflichen Medizin, R. Virchow, ed.), Van Meidlinger Sohn, Frankfurt, pp. 458-636.
146. Vomberg, P.P., Breederveld, C., Fleury, P. and Arts, W.F. (1987) Cerebral thromboembolism due to antithrombin III deficiency in two children. Neuropediatrics. 18: 42-44.
147. Walker, F.J. (1984) Protein S and the regulation of activated protein C. Semin. Thromb. Hemost., 10: 131-138.
148. Ware, R.E., Hall, S.E. and Rosse, W.F. (1991) Paroxysmal nocturnal hemoglobinuria with onset in childhood and adolescence. N. Engl. J. Med., 325: 991-996.
149. Witzum, J.L. and Steinberg, D. (1991) Role of oxidised low density lipoprotein in atherosclerosis. J. Clin. Invest., 88: 1785-1792.
150. Wood, D.H. (1978) Cerebrovascular complications of sickle cell anemia. Stroke, 9: 73-75.